CANF:NYE-Can-Fite BioPharma Ltd (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 1.84

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.38M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. Address: 10 Bareket Street, Petah Tikva, Israel, 49170

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

USD163.53B 28.27 2.82
ADPT Adaptive Biotechnologies Corpo..

N/A

USD5.88B 43.96 N/A
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD5.20B N/A N/A
RCUS Arcus Biosciences, Inc

N/A

USD2.37B N/A N/A
MYOV Myovant Sciences Ltd

N/A

USD1.99B N/A N/A
ADCT ADC Therapeutics SA

N/A

USD1.75B -99,999.99 N/A
ZYME Zymeworks Inc

N/A

USD1.52B 300.20 N/A
CVM CEL-SCI Corporation

N/A

USD0.79B N/A N/A
RFL Rafael Holdings, Inc

N/A

USD0.51B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90

ETFs Containing CANF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.37% 43% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.37% 43% F 51% F
Trailing 12 Months  
Capital Gain 10.18% 28% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.18% 28% F 42% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.07% 12% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.07% 12% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 23.52% 80% B- 33% F
Risk Adjusted Return -25.82% 12% F 19% F
Market Capitalization 0.03B 7% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.30 81% B- 31% F
Price / Cash Flow Ratio -2.75 18% F 85% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -151.30% 26% F 2% F
Return on Invested Capital -616.80% 11% F 0% N/A
Return on Assets -75.73% 22% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.40 71% C- 79% C+
Short Percent N/A N/A N/A N/A N/A
Beta 1.61 48% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.